Advertisement
Research Article| Volume 56, 103232, November 2021

Clinical predictors of disease progression in a cohort of Tunisian progressive Multiple Sclerosis

  • A. Souissi
    Affiliations
    Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia
    Search for articles by this author
  • S. Mrabet
    Affiliations
    Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia

    Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia
    Search for articles by this author
  • A. Nasri
    Affiliations
    Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia

    Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia
    Search for articles by this author
  • M. Ben Djebara
    Affiliations
    Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia

    Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia
    Search for articles by this author
  • A. Gargouri
    Affiliations
    Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia

    Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia
    Search for articles by this author
  • I. Kacem
    Affiliations
    Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia

    Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia
    Search for articles by this author
  • R. Gouider
    Correspondence
    Corresponding author.
    Affiliations
    Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia

    Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia
    Search for articles by this author
Published:August 30, 2021DOI:https://doi.org/10.1016/j.msard.2021.103232

      Highlights

      • In North-Africa, MS exhibits particular characteristics that are mainly related to a more severe phenotype.
      • SPMS and PPMS share common features like age at onset of progression and faster disability rates but differ according to gender and first-relapse characteristics.
      • Median time to reach SPMS is faster for North Africans than Caucasians.

      Abstract

      Background

      Knowledge about progressive Multiple Sclerosis (MS) is mainly based on Caucasian studies. In our North-African context, MS exhibits particular characteristics that are mainly related to a more severe phenotype. Given the limited data available, there is an imminent need to characterize progressive MS in our latitudes.

      Objective

      To describe the specificities of progressive MS and identify the inherent clinical predictors of disability accrual with a Tunisian cohort.

      Methods

      A retrospective, hospital-based study was conducted in the department of neurology of Razi hospital. Patients, who had been diagnosed with MS, were divided into relapsing MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS). Epidemiological, clinical and paraclinical data were compared among the three groups.

      Results

      Of the 504 patients, a progressive MS was described among 115 patients. This percentage of (22.8%) is divided into 13.9% SPMS and 8.9% PPMS. During the first clinical attack, motor symptoms have revealed to be predominant during PPMS (91.1%). For SPMS onset, the median time was 10 years, and was significantly delayed for patients with visual onset or full recovery from the first relapse. Patients with progressive MS exhibited a more rapid disability accumulation.

      Conclusion

      Compared to Caucasians, Tunisians exhibited a faster rate of conversion to SPMS. According to our natural progressive MS history, early clinical features are predictors of MS disability accrual.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abdelhak A.
        • Hottenrott T.
        • Mayer C.
        • Hintereder G.
        • Zettl U.K.
        • Stich O.
        • et al.
        CSF profile in primary progressive multiple sclerosis: re-exploring the basics.
        PLoS One. 2017; 12e0182647
        • Ait Benhaddou E.
        • Alhyan M.
        • Aasfara J.
        • Regragui W.
        • Ibrahimi A.
        • Razine R.
        • et al.
        Multiple sclerosis: clinical characteristics and disability progression in moroccan children.
        J. Neurol. Sci. 2014; 346: 128-132
        • Ammar N.
        • Gouider Khouja N.,.
        • Hentati F
        A comparative study of clinical and paramedical aspects of multiple sclerosis in Tunisia.
        Rev. Neurol. 2006; 162: 729-733
        • Ben hmida M.
        • Samoud S.
        Sclérose en plaques en Tunisie.
        Tunis. Med. 1977; 55: 5-15
        • Confavreux C.
        • Vukusic S.
        Natural history of multiple sclerosis: a unifying concept.
        Brain. 2006; 129: 606-616
        • Confavreux C.
        Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.
        Brain. 2003; 126: 770-782
        • Cottrell D.A.
        • Kremenchutzky M.
        • Rice G.P.
        • Koopman W.J.
        • Hader W.
        • Baskerville J.
        • et al.
        The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.
        Brain. 1999; 122: 625-639
        • Debouverie M.
        • Pittion Vouyovitch S.
        • Louis S.
        • Guillemin F
        Natural history of multiple sclerosis in a population-based cohort.
        Eur. J. Neurol. 2008; 15: 916-921
        • Fambiatos A.
        • Jokubaitis V.
        • Horakova D.
        • Kubala Havrdova E.
        • Trojano M.
        • Prat A.
        • et al.
        Risk of secondary progressive multiple sclerosis: a longitudinal study.
        Mult. Scler. 2020; 26: 79-90
        • Giovannoni G.
        • Cutter G.
        • Sormani M.P.
        • Belachew S.
        • Hyde R.
        • Koendgen H.
        • et al.
        Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive multiple sclerosis hypotheses.
        Mult. Scler. Relat. Disord. 2017; 12: 70-78
        • Hamdy S.M.
        • Abdelnaseer M.
        • Shalaby N.M.
        • Elmazny A.N.
        • Nemr A.A.
        • Hassan A.
        • et al.
        Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study.
        Neuropsychiatr. Dis. Treat. 2017; 13: 1895-1903
        • Harding K.
        • Robertson N.
        Epidemiology of progressive multiple sclerosis.
        (Wilkins A)dir. Progressive multiple Sclerosis. Springer, New York2018: 31-47
        • Hentati E.
        • Bensassi S.
        • Nabli F.
        • Mabrouk T.
        • Zouari M.
        • Hentati F
        Disability progression in multiple sclerosis: a Tunisian prospective cohort study.
        Neurol. Sci. 2018; 39: 879-884
        • Koch M.
        • Kingwell E.
        • Rieckmann P.
        • Tremlett H.
        The natural history of primary progressive multiple sclerosis.
        Neurology. 2009; 73: 1996-2002
        • Kremenchutzky M.
        • Rice G.P.
        • Baskerville J.
        • Wingerchuk D.M.
        • Ebers G.C.
        The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
        Brain. 2006; 129: 584-594
        • Lassmann H.
        Multiple Sclerosis Pathology.
        Cold Spring Harb. Perspect. Med. 2018; 8
        • Lechner Scott J.
        • Spencer B.
        • Malmanche T.
        • Attia J.
        • Fitzgerald M.
        • Trojano M.
        • et al.
        The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude.
        Mult. Scler. 2012; 18: 974-982
        • Leray E.
        • Yaouanq J.
        • Lepage E.
        • Coustans M.
        • Laplaud D.
        • Oger J.
        • et al.
        Evidence for a two-stage disability progression in multiple sclerosis.
        Brain. 2010; 133: 1900-1913
        • Lorscheider J.
        • Buzzard K.
        • Jokubaitis V.
        • Spelman T.
        • Havrdova E.
        • Horakova D.
        • et al.
        Defining secondary progressive multiple sclerosis.
        Brain. 2016; 139: 2395-2405
        • Lublin F.D.
        • Reingold S.C.
        Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis.
        Neurology. 1996; 46: 907-911
        • Lublin F.D.
        • Reingold S.C.
        • Cohen J.A.
        • Cutter G.R.
        • Sørensen P.S.
        • Thompson A.J.
        • et al.
        Defining the clinical course of multiple sclerosis: the 2013 revisions.
        Neurology. 2014; 83: 278-286
        • Musella A.
        • Gentile A.
        • Rizzo F.R.
        • Devito F.
        • Fresegna D.
        • Bullitta S.
        • et al.
        Interplay between age and neuroinflammation in multiple sclerosis: effects on motor and cognitive functions.
        Front Aging Neurosci. 2018; 10: 238
        • Sidhom Y.
        • Damak M.
        • Riahi A.
        • Hizem Y.
        • Mrissa R.
        • Mhiri C.
        • et al.
        Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?.
        J. Neurol. Sci. 2014; 343: 110-114
        • Sidhom Y.
        • Maillart E.
        • Tezenas Montcel S.
        • Kacem I.
        • Lubetzki C.
        • Gouider R.
        • et al.
        Fast multiple sclerosis progression in north africans: both genetics and environment matter.
        Neurology. 2017; 88: 1218-1225
        • Signori A.
        • Gallo F.
        • Bovis F.
        • Di Tullio N.
        • Maietta I.
        • Sormani M.P.
        Long-term impact of interferon or gatiramer acetate in multiple sclerosis: a systematic review and metaanalysis.
        Mult. Scler. Relat. Disord. 2016; 6: 57-63
        • Stys P.K.
        • Tsutsui S.
        Recent advances in understanding multiple sclerosis.
        F1000Res. 2019; 8
        • Stys P.K.
        Pathoetiology of multiple sclerosis: are we barking up the wrong tree?.
        F1000Prime Rep. 2013; 5: 20
      1. The MSBase Foundation. Multiple sclerosis data and findings patient demographics [Internet]. MSbase [cited 2020 Dec 03]. Available from: https://www.msbase.org/data-and-findings/patient-demographics/. 2020.

        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • Carroll W.M.
        • Coetzee T.
        • Comi G.
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the Macdonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Tremlett H.
        • Paty D.
        • Devonshire V.
        Disability progression in multiple sclerosis is slower than previously reported.
        Neurology. 2006; 66: 172-177
        • Tremlett H.
        • Yinshan Z.
        • Devonshire V.
        Natural history of secondary-progressive multiple sclerosis.
        Mult. Scler. 2008; 14: 314-324
        • Vukusic S.
        • Confavreux C.
        Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.
        J. Neurol. Sci. 2003; 206: 135-137
        • Weinshenker B.G.
        • Bass B.
        • Rice G.P.
        • Noseworthy J.
        • Carriere W.
        • Baskerville J.
        • et al.
        The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.
        Brain. 1989; 112: 133-146
        • Westerlind H.
        • Stawiarz L.
        • Fink K.
        • Hillert J.
        • Manouchehrinia A.
        A significant decrease in diagnosis of primary progressive multiple sclerosis: a cohort study.
        Mult. Scler. 2016; 22: 1071-1079